Parkinson's disease and iron.
Iron
Iron chelator
MPTP
PLA2G6
Parkinson's disease
α-synuclein
Journal
Journal of neural transmission (Vienna, Austria : 1996)
ISSN: 1435-1463
Titre abrégé: J Neural Transm (Vienna)
Pays: Austria
ID NLM: 9702341
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
29
12
2019
accepted:
21
01
2020
pubmed:
7
2
2020
medline:
27
3
2021
entrez:
7
2
2020
Statut:
ppublish
Résumé
While the initial causes of Parkinson's disease (PD) are not clearly defined, iron deposition has long been implicated in the pathogenesis of PD. The substantia nigra of PD patients, where the selective loss of dopaminergic neurons occurs, show a fairly selective and significant elevation in iron contents. However, the question remains whether iron deposition represents the initiation cause or merely the consequence of nigral degeneration. Here, we describe existing findings regarding the interaction of iron with neuromelanin and alpha synuclein, the iron deposition in experimental animal model of PD and sporadic and familial PD patients, and the treatment option involving the use of iron chelators for targeting the aberration of iron level in brain. This review may provide us a better understanding of the role of iron in PD to address the question of cause or consequence.
Identifiants
pubmed: 32025811
doi: 10.1007/s00702-020-02149-3
pii: 10.1007/s00702-020-02149-3
doi:
Substances chimiques
Iron Chelating Agents
0
Melanins
0
alpha-Synuclein
0
neuromelanin
0
Iron
E1UOL152H7
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
181-187Subventions
Organisme : Core Research for Evolutional Science and Technology
ID : JPMJCR18H4
Pays : International
Références
J Neurochem. 1989 Feb;52(2):515-20
pubmed: 2911028
Can J Neurol Sci. 1989 Aug;16(3):310-4
pubmed: 2766123
J Neurochem. 2005 Oct;95(1):79-88
pubmed: 16181414
Life Sci. 2020 Jan 1;240:117091
pubmed: 31760102
Bioorg Med Chem. 2005 Feb 1;13(3):773-83
pubmed: 15653345
J Parkinsons Dis. 2011;1(2):205-16
pubmed: 23934922
Biochim Biophys Acta. 2012 Sep;1823(9):1468-83
pubmed: 22610083
Exp Neurol. 2016 Jun;280:13-23
pubmed: 26996132
Sci Rep. 2016 Nov 09;6:36669
pubmed: 27827408
J Med Genet. 2003 Jul;40(7):543-6
pubmed: 12843330
Mol Neurobiol. 2016 Apr;53(3):1925-1934
pubmed: 25833099
Front Aging Neurosci. 2019 Aug 30;11:215
pubmed: 31543809
Brain Res. 2019 Jun 1;1712:25-33
pubmed: 30707893
J Neurochem. 2010 Apr;113(2):454-64
pubmed: 20089134
Neurotox Res. 2011 Jan;19(1):63-72
pubmed: 19957214
Mol Psychiatry. 2007 Mar;12(3):222-3
pubmed: 17325711
Neurobiol Aging. 2013 May;34(5):1497-503
pubmed: 23177595
J Am Chem Soc. 2006 Aug 2;128(30):9893-901
pubmed: 16866548
Toxicol Rep. 2017;4:188-193
pubmed: 28529891
Science. 2003 Oct 31;302(5646):819-22
pubmed: 14593166
Mov Disord. 2018 Nov;33(11):1792-1799
pubmed: 30423212
Science. 2003 Oct 31;302(5646):841
pubmed: 14593171
Mov Disord. 2019 Jul;34(7):1006-1013
pubmed: 31180615
J Neurol. 2006 Jan;253(1):26-32
pubmed: 15981079
Neurotox Res. 2010 Jan;17(1):15-27
pubmed: 19609632
Mov Disord. 2004 Mar;19(3):324-30
pubmed: 15022188
Parkinsons Dis. 2015;2015:324843
pubmed: 25945281
Eur J Neurol. 2017 Feb;24(2):357-365
pubmed: 27982501
Neuropathology. 2015 Jun;35(3):289-302
pubmed: 25950622
Neurology. 2010 Oct 12;75(15):1356-61
pubmed: 20938027
J Neurosci. 2016 Jan 27;36(4):1086-95
pubmed: 26818499
Nature. 1997 Aug 28;388(6645):839-40
pubmed: 9278044
Mov Disord. 2010 Jun 15;25(8):979-84
pubmed: 20310007
Antioxid Redox Signal. 2014 Jul 10;21(2):195-210
pubmed: 24251381
Brain Res. 1996 Jun 10;724(1):125-8
pubmed: 8816266
Ann Neurol. 1999 Oct;46(4):598-605
pubmed: 10514096
Mov Disord. 1996 Jan;11(1):8-16
pubmed: 8771061
Free Radic Biol Med. 2003 Sep 1;35(5):540-7
pubmed: 12927603
Br J Pharmacol. 2001 Jan;132(2):500-6
pubmed: 11159700
J Neurosci. 2000 Aug 15;20(16):6048-54
pubmed: 10934254
J Biol Chem. 2001 Nov 23;276(47):44284-96
pubmed: 11553618
Mech Ageing Dev. 2005 Feb;126(2):317-26
pubmed: 15621213
Lancet. 1987 Nov 21;2(8569):1219-20
pubmed: 2890848
J Neurochem. 2003 Sep;86(5):1142-8
pubmed: 12911622
Neurol India. 2004 Sep;52(3):332-7
pubmed: 15472421
Ann Neurol. 2009 Jan;65(1):19-23
pubmed: 18570303
Eur J Radiol. 2018 Dec;109:48-56
pubmed: 30527311
ACS Chem Neurosci. 2016 Jan 20;7(1):119-29
pubmed: 26481462
Neuropharmacology. 2004 Feb;46(2):254-63
pubmed: 14680763
Parkinsonism Relat Disord. 2001 Oct;7(4):311-314
pubmed: 11344015
J Neurochem. 1994 Jan;62(1):134-46
pubmed: 8263513
Nat Genet. 2006 Jul;38(7):752-4
pubmed: 16783378
Am J Hum Genet. 2006 Nov;79(5):942-8
pubmed: 17033970
PLoS One. 2015 Oct 27;10(10):e0141629
pubmed: 26506412
J Biol Chem. 2008 Apr 18;283(16):10992-1003
pubmed: 18258594
J Neurosci. 2011 Aug 3;31(31):11411-20
pubmed: 21813701
J Trace Elem Med Biol. 2014 Jan;28(1):13-7
pubmed: 24075790
Neuron. 2003 Mar 27;37(6):899-909
pubmed: 12670420
J Neural Transm (Vienna). 2017 Aug;124(8):973-981
pubmed: 28168622
J Neuropathol Exp Neurol. 1968 Jan;27(1):114-5
pubmed: 4968527
J Neurochem. 1992 Sep;59(3):1168-71
pubmed: 1494904
Biochim Biophys Acta Mol Cell Res. 2017 Feb;1864(2):399-430
pubmed: 27939167
J Neural Transm (Vienna). 2002 May;109(5-6):663-72
pubmed: 12111458
Neurosci Lett. 1994 Feb 28;168(1-2):251-3
pubmed: 8028787
Neurotox Res. 2003;5(1-2):35-44
pubmed: 12832223
Biochim Biophys Acta. 2015 Aug;1848(8):1646-55
pubmed: 25912790
ACS Chem Neurosci. 2011 Nov 16;2(11):667-75
pubmed: 22860160
Mov Disord. 2019 Mar;34(3):416-419
pubmed: 30597635
J Neurol Sci. 2017 Nov 15;382:61-65
pubmed: 29111022
J Neurochem. 2008 Aug;106(4):1866-75
pubmed: 18624918
Acta Neurol Scand Suppl. 1989;126:47-54
pubmed: 2618593
Neurogenetics. 2011 Feb;12(1):33-9
pubmed: 20853184